Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV‑2 Antiviral Activities and Lack of Translatability

Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV‑2 Antiviral Activities and Lack of Translatability

The antiparasitic drug ivermectin was proposed as a repurposed drug for the treatment of SARS-CoV-2 infection based on in vitro studies, but proved ineffective in high-quality clinical trials. When exploring possible reasons for this disconnect, we found that ivermectin interferes with AlphaScreen a...

Full description

Saved in:
Bibliographic Details
Main Author: Richard T. Eastman (6051881) (author)
Other Authors: Radda Rusinova (4870042) (author), Karl F. Herold (605487) (author), Xi-Ping Huang (391870) (author), Ty Voss (12046550) (author), Alex D. White (7356104) (author), Hugh C. Hemmings (1330833) (author), Olaf S. Andersen (823886) (author), Jayme L. Dahlin (486120) (author)
Published: 2025
Subjects:
Biochemistry
Medicine
Pharmacology
Biotechnology
Cancer
Infectious Diseases
Virology
Computational Biology
Chemical Sciences not elsewhere classified
Information Systems not elsewhere classified
quality clinical trials
perturbing bioactivity early
low nanomolar concentrations
low micromolar concentrations
highlight lessons learned
exploring possible reasons
2 viral burden
2 infection based
safe antiparasitic drug
antiparasitic drug ivermectin
ivermectin reduced sars
effective antiviral agent
antiviral agent
repurposed drug
drug development
pursuing ivermectin
ivermectin interferes
ivermectin explain
proved ineffective
perspective </
original justifications
membrane perturbations
level rationale
identifying membrane
becomes cytotoxic
assay interferences
alphascreen assays
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items